NLRP3 and Obesity: Alleviation of obesity‐associated inflammation via NLRP3 inhibition 1) constitutes an effective weight‐loss strategy as monotherapy in mice with DIO, 2) augments the weight‐loss efficacy of a subtherapeutic dose of semaglutide, and 3) blocks recovery of lost weight following cessation of semaglutide.